O DIAGNÓSTICO CERTO PARA CADA PESSOA: Plataformas moleculares polivalentes e de alto desempenho para detecção precoce de casos e tratamento imediato da TB e TB-DR

Speakers
  • Universidade Addis Ababa, Faculdade de Ciências da Saúde, Centro de Desenvolvimento Inovador de Medicamentos e Ensaios Terapêuticos para África,
    Biography

      Dr. Manyazewal has extensive experiences and an expert in infectious diseases management and public health policy, especially in the fight to end tuberculosis. He has authored and co-authored over 47 publications. Dr. Manyazewal has worked at University of California San Diego, Mayo Clinic, University of Maryland School of Medicine and Johns Hopkins University US PEPFAR programs in Ethiopia.

    • Microbiologista Clínico / Imunologista Muhimbili Universidade de Saúde e Ciências Afins, Tanzânia
      Biography

        Dr. Majigo has extensive experience in health related activities including research, capacity building, program implementation and laboratory management through working with national and international organizations. He serves as consultant for Antimicrobial Resistance (AMR) surveillance in Tanzania. He was instrumental in development of the National Antimicrobial Resistance Action Plan and AMR Surveillance Framework. He participates in activities coordinated by the Department of Microbiology and Immunology including, teaching, research, consultancy and provision of public service. Dr. Majigo has been involved in several studies of infectious disease specifically HIV, TB, sexually transmitted disease, Rubella, and bacterial infection.


      Abstract

      Avançando para as metas globais de TB END 2035, o acesso a ferramentas precisas de diagnóstico de TB e DR-TB são necessários mais do que nunca. Como consequência direta do COVID-19, estima-se 6,3 milhões de novos casos de TB e 1,4 milhão de mortes entre 2020 e 2025, e os países com alta carga permanecerão no topo. Há uma forte necessidade de aumentar a capacidade de diagnóstico preciso da TB e da DR-TB, pois pessoas doentes com COVID-19 e TB apresentam sintomas semelhantes. Grandes progressos foram feitos para um diagnóstico rápido e preciso da TB e da DR-TB usando ensaios moleculares em tempo real e isso poderia aproveitar os achados de casos de TB no surto de COVID-19. Este webinar pretende trocar opiniões sobre o papel e contribuições de plataformas moleculares polivalentes e de alto rendimento na descoberta precoce de casos e tratamento imediato de TB e DR-TB. Consiste em três áreas de foco: o algoritmo de diagnóstico atual para TB e DR-TB em países de alta carga; a necessidade de capacidade laboratorial para DR-TB e impacto na população; e o poder das plataformas de diagnóstico polivalente para abordar os achados de casos de TB e DR-TB no surto de COVID-19.

       

      Objetivos de aprendizagem:

       

      • Entenda os desafios atuais de testes e plataformas de MTB e RIF/INH 
      • Entenda a utilidade clínica dos testes de resistência mTB e RIF/INH no gerenciamento de pacientes com TB
      • Entenda o processo de fluxo de trabalho para implementar testes de mTB em áreas que precisam de scaleup e automação


       

       

       

       

      Webinars estarão disponíveis para sob demanda ilimitada por 12 meses


      Show Resources
      You May Also Like
      NOV 18, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 18, 2020 8:00 AM PST
      DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
      MAY 11, 2021 10:00 AM PDT
      C.E. CREDITS
      MAY 11, 2021 10:00 AM PDT
      Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
      FEB 24, 2021 10:00 AM PST
      C.E. CREDITS
      FEB 24, 2021 10:00 AM PST
      DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
      MAR 16, 2021 10:00 AM PDT
      C.E. CREDITS
      MAR 16, 2021 10:00 AM PDT
      Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
      APR 01, 2021 8:00 AM PDT
      C.E. CREDITS
      APR 01, 2021 8:00 AM PDT
      Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
      DEC 03, 2020 4:30 PM PST
      C.E. CREDITS
      DEC 03, 2020 4:30 PM PST
      This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
      Loading Comments...
      Show Resources
      Attendees
      • See more